Cargando…

Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer

INTRODUCTION: Programmed death-ligand 1 (PD-L1) expression as measured by immunohistochemistry (IHC) has been employed to predict the efficacy of anti-PD-1/PD-L1 therapy. Nevertheless, heterogeneous PD-L1 expression represents a challenge for the selection of patients for anti-PD-1/PD-L1 therapy. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haipeng, Chen, Xueyan, Lin, Dong, Zhang, Jing, Li, Chao, Zhang, Dianbao, Zhang, Xianfen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941607/
https://www.ncbi.nlm.nih.gov/pubmed/31920342
http://dx.doi.org/10.2147/OTT.S223643
_version_ 1783484572991750144
author Xu, Haipeng
Chen, Xueyan
Lin, Dong
Zhang, Jing
Li, Chao
Zhang, Dianbao
Zhang, Xianfen
author_facet Xu, Haipeng
Chen, Xueyan
Lin, Dong
Zhang, Jing
Li, Chao
Zhang, Dianbao
Zhang, Xianfen
author_sort Xu, Haipeng
collection PubMed
description INTRODUCTION: Programmed death-ligand 1 (PD-L1) expression as measured by immunohistochemistry (IHC) has been employed to predict the efficacy of anti-PD-1/PD-L1 therapy. Nevertheless, heterogeneous PD-L1 expression represents a challenge for the selection of patients for anti-PD-1/PD-L1 therapy. METHODS: PD-L1 expression using clone 22C3 in 76 resected non-small-cell lung cancer and paired nodal metastases was assessed and classified according to the proportion of immunostained tumour cells using cutoff values of 1%, 5%, and 50%. RESULTS: The concordance rates for PD-L1 expression between primary and metastatic lymph nodes (N1) at these cutoff values were 67.7% (21/31) (Kappa value: 0.455, p<0.000), 60.0% (15/25) (Kappa value: 0.668, p<0.000), and 62.5% (5/8) (Kappa value: 0.497, p<0.000). In 36 paired N1 lymph nodes and N2 lymph nodes, 54.5% (6/11) (Kappa value: 0.625, p<0.000) of cases of PD-L1 expression were coincident at cutoffs of 1%. If stratified by adenocarcinoma and squamous cell carcinoma, 87.5% (14/16) (Kappa value: 0.830, p<0.000) of cases at the 1% cutoff and 46.7% (7/15) (Kappa value: 0.324, p<0.000) of cases at the 1% cutoff were coincident. CONCLUSION: The results of this study demonstrate that the concordance of PD-L1 expression between primary tumour and nodal metastases is low in non-small-cell lung cancer but is high in adenocarcinoma. Our results also suggest that PD-L1 expression in either lymph nodes or tumour tissues does not predict survival. PD-L1 detection in metastatic lymph nodes is not a suitable replacement for PD-L1 detection in the primary lesion.
format Online
Article
Text
id pubmed-6941607
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69416072020-01-09 Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer Xu, Haipeng Chen, Xueyan Lin, Dong Zhang, Jing Li, Chao Zhang, Dianbao Zhang, Xianfen Onco Targets Ther Original Research INTRODUCTION: Programmed death-ligand 1 (PD-L1) expression as measured by immunohistochemistry (IHC) has been employed to predict the efficacy of anti-PD-1/PD-L1 therapy. Nevertheless, heterogeneous PD-L1 expression represents a challenge for the selection of patients for anti-PD-1/PD-L1 therapy. METHODS: PD-L1 expression using clone 22C3 in 76 resected non-small-cell lung cancer and paired nodal metastases was assessed and classified according to the proportion of immunostained tumour cells using cutoff values of 1%, 5%, and 50%. RESULTS: The concordance rates for PD-L1 expression between primary and metastatic lymph nodes (N1) at these cutoff values were 67.7% (21/31) (Kappa value: 0.455, p<0.000), 60.0% (15/25) (Kappa value: 0.668, p<0.000), and 62.5% (5/8) (Kappa value: 0.497, p<0.000). In 36 paired N1 lymph nodes and N2 lymph nodes, 54.5% (6/11) (Kappa value: 0.625, p<0.000) of cases of PD-L1 expression were coincident at cutoffs of 1%. If stratified by adenocarcinoma and squamous cell carcinoma, 87.5% (14/16) (Kappa value: 0.830, p<0.000) of cases at the 1% cutoff and 46.7% (7/15) (Kappa value: 0.324, p<0.000) of cases at the 1% cutoff were coincident. CONCLUSION: The results of this study demonstrate that the concordance of PD-L1 expression between primary tumour and nodal metastases is low in non-small-cell lung cancer but is high in adenocarcinoma. Our results also suggest that PD-L1 expression in either lymph nodes or tumour tissues does not predict survival. PD-L1 detection in metastatic lymph nodes is not a suitable replacement for PD-L1 detection in the primary lesion. Dove 2019-12-30 /pmc/articles/PMC6941607/ /pubmed/31920342 http://dx.doi.org/10.2147/OTT.S223643 Text en © 2019 Xu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xu, Haipeng
Chen, Xueyan
Lin, Dong
Zhang, Jing
Li, Chao
Zhang, Dianbao
Zhang, Xianfen
Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer
title Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer
title_full Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer
title_fullStr Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer
title_full_unstemmed Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer
title_short Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer
title_sort conformance assessment of pd-l1 expression between primary tumour and nodal metastases in non-small-cell lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941607/
https://www.ncbi.nlm.nih.gov/pubmed/31920342
http://dx.doi.org/10.2147/OTT.S223643
work_keys_str_mv AT xuhaipeng conformanceassessmentofpdl1expressionbetweenprimarytumourandnodalmetastasesinnonsmallcelllungcancer
AT chenxueyan conformanceassessmentofpdl1expressionbetweenprimarytumourandnodalmetastasesinnonsmallcelllungcancer
AT lindong conformanceassessmentofpdl1expressionbetweenprimarytumourandnodalmetastasesinnonsmallcelllungcancer
AT zhangjing conformanceassessmentofpdl1expressionbetweenprimarytumourandnodalmetastasesinnonsmallcelllungcancer
AT lichao conformanceassessmentofpdl1expressionbetweenprimarytumourandnodalmetastasesinnonsmallcelllungcancer
AT zhangdianbao conformanceassessmentofpdl1expressionbetweenprimarytumourandnodalmetastasesinnonsmallcelllungcancer
AT zhangxianfen conformanceassessmentofpdl1expressionbetweenprimarytumourandnodalmetastasesinnonsmallcelllungcancer